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Abstract             
 
G protein-coupled receptors (GPCRs) are seven-pass transmembrane proteins that 
facilitate major physiological processes in humans. GPCRs are targets of more than 40% of 
therapeutic drugs, which lead to activation of intracellular signal transduction proteins 
(transducers). Drugs targeting GPCRs have recently been shown to have preference for certain 
transduction pathways, a phenomenon termed functional selectivity. Drugs that are biased to 
exclusively activate one transduction pathway have been found to be more efficacious and 
produce fewer side effects. Therefore, understanding the nature of a ligand’s preference for a 
particular transduction pathway may lead to the development of novel drugs with superior 
therapeutic efficacy. No methods have been developed to specifically characterize the 
transducer-dependent interaction of a GPCR and its ligand across multiple transducers. The Roth 
laboratory at UNC is developing a screening platform for this purpose. We utilized this platform 
and fused the dopamine D2 receptor (D2R), the primary target for antipsychotic drugs, to 17 
human transducers. We then performed in vitro competitive radioligand binding assays with D2-
selective drug, quinpirole, and the D2R endogenous ligand, dopamine. The signaling profiles 
produced indicated that dopamine and quinpirole exhibit high affinity for D2R fused to canonical 
Gαi transducers and quinpirole lacks high affinity toward non-canonical Gα transducers. These 
results align with previous knowledge of the D2 dopamine receptor, and therefore provide 
validation for the screening platform used. We anticipate these signaling profiles will give 
insight into functional selectivity that may be utilized for therapeutic advancement of 
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Introduction             
 
Until recently, pharmacological theory has postulated that a ligand’s ability to occupy a G 
protein-coupled receptor (GPCR), and therefore activate a response pathway, was solely 
dependent on the inherent properties of the ligand-receptor pair. This is described as intrinsic 
efficacy, a phenomenon that has been greatly relied upon for the last half-century (Urban et al., 
2007).  Intrinsic efficacy depicts a system-independent outcome that is constant for each ligand 
at a given receptor, regardless of where the receptor is expressed. However, it has been found 
that some molecules, such as dopamine receptor agonists, do not follow this system-independent 
pattern for agonist-receptor complexes.  These agonists are described as being “biased” toward 
certain transduction pathways, a phenomenon termed “functional selectivity”.  
GPCRs are the target of more than 40% of therapeutic drugs (Filmore, 2004), and 
therefore it is important to consider functional selectivity during drug discovery and 
development. Since a molecule’s efficacy and affinity at a certain receptor may vary depending 
on environment, it may be possible to find drugs that are more efficacious and/or have less side 
effects by understanding the nature of the drug’s bias for particular signal transduction pathways 
(transducers). For example, drugs may be optimized to target a specific transduction pathway 
that is characteristic of a particular tissue to avoid side effects in parts of the body that are not 
being targeted (Civelli, Bunzow, & Grandy, 1993). A GPCR of pharmacological significance is 
the D2 dopamine receptor (D2R), encoded by the DRD2 gene. This receptor is targeted by a 
variety of traditional and newer drugs to treat mental health conditions such as schizophrenia and 
Parkinson’s disease (Seeman, 2006).  In fact, the ability to interact with dopamine D2 receptors 
is a shared quality of all clinically effective antipsychotics (Masri et al., 2008). Further 
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comprehension and discovery related to agonists’ affinity at GPCRs of interest, such as D2R, 
will allow for expansion and improvement of drugs and therapies.  
Currently, little is known about the relationship between an agonist’s ability to signal at a 
receptor and the transducers bound to that receptor. In order to provide insight to this unknown, 
the Roth laboratory is developing a screening platform to characterize ligand bias towards 
individual transducer-coupled receptors. This platform is an expansion of pilot work done by Dr. 
Ryan Strachan (Strachan et al., 2014). Using methods from Dr. Strachan’s study, we fused D2R 
to 17 human transducers and then performed in vitro competitive radioligand binding assays with 
quinpirole, a D2-selective drug, and dopamine, the endogenous D2R ligand (Figure 1).  Drawing 
upon established knowledge of the dopamine D2 receptor (Montmayeur, Guiramand, & Borrelli, 
1993), we predicted that quinpirole and dopamine would exhibit high affinity for D2R bound to 
its canonical transducer proteins, Gαi (also denoted as Ga(i)), and lack high affinity for D2R 
bound to non-canonical Gα transducers.  
The signaling profiles produced from this assay, as demonstrated in the results section, 
were consistent with our prediction. This data provides information about the relationship 
between ligand, receptor, and transducer for the dopamine D2 receptor that is independent of in 
vivo variables, such as the presence of other proteins in a cell’s internal environment. 
Additionally, the results provide validation for the screening platform. We anticipate that these 
profiles, along with future profiles produced using this platform, will provide insight into 
functional selectivity that is useful for therapeutic advancement of antipsychotic drugs. 
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Figure 1. The chemical structures of dopamine and quinpirole. Dopamine, the endogenous 
ligand for the dopamine D2 receptor, binds to the D2R active state. Quinpirole, a D2-selective 
drug, also binds strongly to the D2R active state. Quinpirole lacks free rotating bonds and has 





Methods             
Creating D2R-transducer fusions 
Prior to fusing the 17 transducer elements to the D2 receptor, each transducer component 
was PCR amplified using Primestar MAX DNA Polymerase according to manufacturer’s 
instructions. Forward and reverse primers used to amplify each transducer were from Eton 
Biosciences and are listed in Tabe 1. The amplified transducer elements were verified via gel 
imaging (Fig. 2) and sequencing (Genewiz) (Fig. 3). Gel imaging was done with 1% agarose gels 
in 1X TAE buffer and ran for 30 minutes at 150 V. Bands were visualized via UV illumination 
with 0.5 µg/mL ethidium bromide as the DNA dye.  
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Figure 2. Gel image of amplified human transducer elements. Elements confirmed to be around 




Figure 3. Example of amplification verification via sequencing, shown for D2-β arrestin 2 fusion 
with forward primer. Template base code indicated in top row. Clean peaks verify proper 







1 kb - 
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GaS short CTGTACTTCCAGCTAATGGGCTGCCTCGGGAACAG CTAGACTCGAGCTATTATAGCAGCTCGTACTGACGA
AG 
GaS long CTGTACTTCCAGCTAATGGGCTGCCTCGGGAACAG CTAGACTCGAGCTATTAGAGCAGCTCGTACTGACGA
AGG 
GaO A CTGTACTTCCAGCTAATGGGATGTACTCTGAGCGC CTAGACTCGAGCTATCAGTACAAGCCGCAGCCCC 
GaO B CTGTACTTCCAGCTAATGGGATGTACTCTGAGCGC CTAGACTCGAGCTATCAGTAGAGTCCACAGCCCCG 
Ga(i) 1 CTGTACTTCCAGCTAATGGGCTGCACGCTGAGCGC CTAGACTCGAGCTATTAAAAGAGACCACAATCTTTTA
GATTATTTTTTATGATG 
Ga(i) 2 CTGTACTTCCAGCTAATGGGCTGCACCGTGAGCGC CTAGACTCGAGCTATCAGAAGAGGCCGCAGTCCTT
C 






β-arrestin 1 CTGTACTTCCAGCTAATGGGCGACAAAGGGACCCG CTAGACTCGAGCTACTATCTGTTGTTGAGCTGTGGA
G 
β-arrestin 2 CTGTACTTCCAGCTAATGGGGGAGAAACCCGGGAC CTAGACTCGAGCTACTAGCAGAGTTGATCATCATAG
TCGTC 
Table 1. Primers used for amplification of transducer elements.  
 
 
	   7 
The D2R GPCR (DRD2-Tango from addgene.org) (Kroeze et al., 2015) was amplified 
using Primestar MAX DNA according to manufacturer’s instructions. Primers used for 
amplification were transfus-tangobbf (TAGCTCGAGTCTAGAGGG) and transfus-tangobbr 
(TAGCTGGAAGTACAGGTTC).  
All DNA amplification was done using 10-beta competent E. coli cells. DNA was 
purified using Zymo mini-prep kit according to manufacturer’s instructions. Zymo midi-prep kit 
was used according to manufacturer’s instructions for full DNA preparation for transfection. 
The GPCR-transducer fusions were then generated using homologous recombination 
cloning with NEBuilder Hi-Fi DNA Assembly Master Mix, according to manufacturer’s 
instructions. Successful incorporation of the transducer was confirmed via gel imaging (Fig. 4) 
and sequencing (Genewiz) (Fig. 3). Sequencing confirmation was done with primers BGHR 
(TAGAAGGCACAGTCGAGG), CMV-Forward (CGCAAATGGGCGGTAGGCGTG), 
TangoTransFusSeq-F(V2tail-F) (GGGTCCCCAAGATGAGTCCTGC) and TangoTransFusSeq-
R(V2tail-R) (GCAGGACTCATCTTGGGGACCC).  General plasmid design of final fusion 
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Figure 4. Gel image of fusion constructs. Successful insertion of transducer into DRD2-Tango 
backbone is visualized by appropriate size, about 3,000 base pairs. 1 kb ladder used as reference 





Figure 5. General plasmid design for GPCR-transducer fusion proteins. Arrows indicate primer 
sites for PCR verification of fusions used to generate Figure 4. Includes signal for 
overexpression in membrane, a FLAG affinity tag for visualizing receptor expression, 
Vasopressin 2 receptor (V2R) C-terminus as a linker and arrestin recruitment domain, and a 
TEV protease cleavage site to remove fused transducer for control experiments. 
 
 
Expression and membrane preparation of DRD2-transducer fusion proteins 
HEK293T cell membranes were transfected using a modified calcium phosphate method 
(Jordan, Schallhorn, & Wurm, 1996). Briefly, cells were transfected with 20 µg of D2 fusion 
cDNA and allowed to express for at least 48 hours. On the day of membrane preparation, media 
1 kb - 
3 kb - 
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was decanted and cells were in 10 mL ice-cold lysis buffer (1 mM HEPES, 2 mM EDTA, pH 
7.4) and left at 4°C for at least 10 minutes. Cell lysates were re-suspended, transferred to 30 mL 
centrifuge tubes, and centrifuged at 30,000xg for 30 minutes at 4°C. Tubes were decanted and 
membrane pellets were re-suspended in 4 mL/15 cm plate of Standard Binding Buffer (SBB; 50 
mM Tris-HCl, 10 mM MgCl2, 0.1 mM EDTA, pH 7.4). Cells were re-suspended using a 
mechanical homogenizer (Polytron, setting 4) for 5 seconds, and 1 mL aliquots of the re-
suspension were transferred to pre-chilled 1.7 mL microcentrifuge tubes. Re-suspended 
membranes were then centrifuged at 13,000xg for 10 minutes at 4°C. The SBB was decanted and 
membrane pellets were stored at -80°C until use. 
 
Competitive radioligand binding 
Competition binding assays were used to estimate shifts in affinity comparing D2R unfused to 
D2-fused receptors. Receptors were labeled with radioactive D2R antagonist [3H] N-methyl 
spiperone (0.1 nM, effective concentration with 50% effect (EC50)) (Figure 6) and tested in 
competition with 11 concentrations in duplicate to generate a KHi and KLo (Strachan et al., 
2014). Binding assays were performed in 96-well plates with 150 µL per well of SBB containing 
0.1% bovine serum albumin (BSA) and 0.01% ascorbic acid. Receptors were incubated for at 
least 3 hours at 25°C in the dark to achieve equilibrium. Reactions are stopped by vacuum 
filtrations onto 0.3% polyethyleneimine-soaked 96-well filter mats using a 96-well Filtermate 
harvester, followed by at least 3 washes of cold wash buffer. Scintillation (MeltiLex) cocktail is 
melted onto dried filters and radioactivity is counted using a Wallac Trilux Microbeta (Perkin 
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Elmer). Data was quantified and graphed using Prism 6.0 software and methods from Strachan et 













Results             
  [3H]-N-methyl spiperone, the radioligand, showed no significant high affinity shifts for 
the fusions with canonical transducers of interest, Ga(i)1,2,3 (Fig. 7) . This demonstrates that 
[3H]-N-methyl spiperone is neutral and nonselective for these transducers. [3H]-N-methyl 
spiperone is therefore an appropriate radioligand for this assay. 
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Figure 7.  Binding curves for [3H] N-Methyl spiperone. No significant high affinity shifts for this 
radioligand at any fusions with canonical transducers of interest (Ga(i)1,2,3). Data is from three 
(n=3) separate set-ups and runs with [3H] N-Methyl spiperone. 
	  
Quinpirole, a D2-selective drug, was tested with twelve of the transducer fusions (Figure 
8). Quinpirole showed high-affinity site binding shifts for canonical transducers Ga(i)1, Ga(i)2, 
and Ga(i)3.  The high- and low-affinity half maximal inhibitory concentration (IC50Hi and 
IC50Lo, respectively) for the fusion curves was used to determine fold shift from the D2-unfused 
receptor curve. Quinpirole showed a 30-fold shift with Ga(i)1, a 118-fold shift with Ga(i)2, and a 
68-fold shift with Ga(i)3 (Figure 9).  These shifts demonstrated significant bias for the canonical 
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Figure 8. Quinpirole binding curves for 12 transducer-fusions. Quinpirole showed high-affinity 
site binding shifts for canonical transducers Ga(i)1, Ga(i)2, and Ga(i)3, taken from three (n=3) 
sets of data. Significant shifts were not detected for other transducers, performed with two 
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Figure 9. Quinpirole 
high-affinity site binding 
shifts at the Ga(i)1, 2, 
and 3 transducers. D2-
Ga(i)1 fusion showed a 
30-fold shift in its high 
affinity IC50 (IC50Hi = 
47.6 nM) relative to the 
low affinity IC50 
(IC50Lo =1416 nM) (a). 
D2-Ga(i)2 fusion 
showed a 118-fold shift 
in its high affinity IC50 
(IC50Hi =11.3 nM) 
relative to the low 
affinity IC50 (IC50Lo 
=1332 nM) (b). D2-
Ga(i)3 fusion showed a 
68-fold shift in its high 
affinity IC50 (IC50Hi 
=21.7 nM) relative to 
low affinity IC50 
(IC50Lo = 1473 nM) (c). 
All three fold-shift 




binding sites for 
quinpirole. (n=3) for 
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Quinpirole showed no significant affinity shifts for non-canonical transducers, including 

























































were detected for 
D2-Ga(s) long or 
D2-Ga(s) short 
fusions (a). No 
significant shifts 
were detected for 
D2-Ga(q), D2-
Ga(z), or D2-
Ga(olf) fusions (b). 
(n=2) for (a) and 
(b).  
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Dopamine, the endogenous D2R ligand, was also found to show high-affinity site binding 
shifts for canonical Ga(i) transducers (Figure 11). The high- and low-affinity half maximal 
inhibitory concentration for the fusion curves was used to determine fold shift from the D2-
unfused receptor. Dopamine showed a 181-fold shift with Ga(i)1, a 81-fold shift with Ga(i)2, and 
a 19-fold shift with Ga(i)3 (Figure 12).  The fold shifts indicate that dopamine significantly 
showed preference for Ga(i)1, Ga(i)2, and Ga(i)3.   
	  
	  
Figure 11. Dopamine binding curves for canonical Ga(i) transducers. Dopamine showed high-
affinity site binding shifts for canonical transducers Ga(i)1, Ga(i)2, and Ga(i)3. Data taken from 

















































































































Figure 12. Dopamine 
high-affinity site 
binding shifts at the 
Ga(i)1, 2, and 3 
transducers. D2-
Ga(i)1 fusion showed 
a 181-fold shift in its 
high affinity IC50 
(IC50Hi = 2.3 nM) 
relative to the low 
affinity IC50 (IC50Lo 
=419.7 nM) (a). D2-
Ga(i)2 fusion showed 
a 81-fold shift in its 
high affinity IC50 
(IC50Hi =4.5 nM) 
relative to the low 
affinity IC50 (IC50Lo 
=368.3 nM) (b). D2-
Ga(i)3 fusion showed 
a 19-fold shift in its 
high affinity IC50 
(IC50Hi =22.7 nM) 
relative to low affinity 
IC50 (IC50Lo = 423.1 
nM) (c). All three fold-
shift values for the 
Ga(i) transducers 
were significant in 
determining high-
affinity binding sites 
for dopamine. (n=3) 




	   17 
Discussion             
Our assay provides insight into the functional selectivity of quinpirole and dopamine at 
the dopamine D2 receptor. Quinpirole, a D2-selective drug, and dopamine, the D2R endogenous 
ligand, both showed high affinity shifts for D2R fused to canonical Gαi transducers (Figures 9, 
11, 12). Quinpirole did not show high affinity shifts for non-canonical Gα transducers (Figure 
10). This data is consistent with our predictions and the accepted knowledge of the nature of the 
dopamine D2 receptor (Lane, Powney, Wise, Rees, & Milligan, 2007) and therefore provides 
validation for the developing screening platform used in the Roth laboratory. 
The fusion constructs created were designed to express D2R fused to one transducer. The 
subsequent isolation of the complexes allowed for in vitro binding assays that would provide 
data without in vivo variables, such as the presence of other proteins and transducers in a cell’s 
internal environment. Therefore, it is understood that the signaling profiles produced provide 
data that is result of the definitive receptor-transducer pair. The variations in affinity can be 
attributed to the presence of a transducer at the receptor, as seen with the quinpirole and 
dopamine data presented here. 
This screening platform can be utilized to investigate ligands’ pharmaceutical potential. 
Expression of transducers is cell- and tissue-type dependent (Sharma et al., 2015). By 
understanding a ligand’s varying preference for transducers, this differential transducer 
expression could be used to design optimized drugs. For example, transducer Ga(i)3 is found to 
be highly expressed particularly in mouse optic nerve cells (Sharma et al., 2015). If a drug is 
found to be functionally selective for Ga(i)3, it may be speculated that it would target optic nerve 
cells with minimal activity at cells that do not possess Ga(i)3. This hypothetical drug would 
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likely be more efficacious and trigger less side-effects than a drug that was not characterized as 
having high affinity for Ga(i)3.    
In addition to facilitating new drug design, our platform can uncover novel biology 
occurring between current pharmaceutical and their targeted receptors. This information will 
allow for clearer understanding of a drug’s preference for particular transducers, therefore 
prompting speculation of the drug’s effects on a body-wide scale. For example, the serotonin 5-
HT2A  receptor is mostly known for its expression in the central nervous system and is clinically 
targeted accordingly. However, 5-HT2A is also highly expressed in the intestine, platelets, and 
endothelial cells (Raote, Bhattacharya, & Panicker, 2007).  Using our platform to create affinity 
profiles for 5-HT2A-targeted drugs may reveal new information about the drug’s behavior at the 
body’s different cell types, considering that transducer expression is differential between cells 
and tissues. This insight may then uncover new uses for the drug or allow for modification of the 
drug to reduce its effects at untargeted sites of the body.  
To further broaden and develop this platform, more ligands should be tested against our 
D2R transducer fusions. This may include characterizing known clinical antipsychotics that are 
D2R-targeted, such as aripiprazole which is prescribed to treat schizophrenia (Burris et al., 2002) 
and bipolar disorder (Kanba et al., 2012). Additionally, other GPCRs of pharmacological 
importance can be used for fusions in order to create high-affinity profiles for a variety of drugs. 
For our next step, the Roth lab plans to expand this screening platform by creating fusions with 
the aforementioned serotonin 5-HT2A receptor, the target of clinical drugs such as mirtazapine 
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